HYBRID EVENT: You can participate in person at Singapore or Virtually from your home or work.

6th Edition of International Conference on

Materials Science and Engineering

March 18-20, 2024 | Singapore

Materials 2024

Yong Teng

Speaker at Materials Science and Engineering 2024 - Yong Teng
Emory University, United States
Title : In vivo delivery of CRISPR Cas9 using lipid nanoparticles enables gene depletion to enhance immunotherapy in cancer


Cancer acquires and metabolizes nutrients through aerobic glycolysis, synthesizing macromolecular precursors to support cancer cell survival. Therefore, targeting cancer metabolic oncoproteins represents a new concept in the development of effective cancer therapeutics. PFKP, also known as platelet phosphofructokinase, is an enzyme that plays a critical role in cellular metabolism. It is involved in the regulation of glycolysis, the metabolic pathway that converts glucose into energy. Our previous study demonstrated elevated expression of PFKP in head and neck squamous cell carcinoma (HNSCC) primary tissues and cultured cell lines. Loss of function suppresses HNSCC cell growth and induces tumor regression in orthotopic tumor-bearing mice. Several inhibitors targeting glycolytic enzymes, including PFKP, are being investigated in preclinical and clinical trials as potential anticancer agents, but the overall response rate remains low. CRISPR-Cas9 has revolutionized genome engineering and has been widely used to modify cancer-associated genes. However, challenges remain as CRISPR editing components must be transported into cells to exert their function. There is a need to explore effective in vivo delivery systems to accelerate the clinical application of CRISPR-Cas9. We recently developed CRISPR-based PFKP-targeting nanodrugs by loading Cas9 mRNA and anti-PFKP sgRNAs into lipid nanoparticles (LNPs), which have become a clinically acceptable delivery system due to their low toxicity and high delivery efficacy and biocompatibility. As expected, LNP-sgPFKP treatment of tongue tumors established in immunocompetent C57BJ/6 mice remarkably suppressed tumor growth. Most interestingly, LNP-sgPFKP acted synergistically with anti-PD1 antibody and significantly primed CD8+ T cells, resulting in durable anticancer activity against HNSCC compared to monotherapy. These novel and significant findings demonstrate a novel approach to inhibit PFKP in tumor cells and provide a potential therapeutic strategy to enhance the success of multimodality therapy in cancer patients.

Audience Take Away Notes:

  • We will present recent advances in the field of nanoparticle-mediated targeted therapeutics for head and neck cancer, with a focus on target sites
  • We will also demonstrate the tremendous potential of nanoparticle-based targeted therapeutics to address the need for viable alternative cancer therapies and encourage the audience to further explore more specific tumor targets and more efficient nanocarriers


Dr. Yong Teng, PhD, is an associate professor of the Department of Hematology and Medical Oncology at Emory University, USA. He is the inaugural recipient of the Wally Award from Winship Cancer Institute of Emory University and a fellow of IAAM and VEBLEO. He is an active member of the International Head and Neck Scientific Group, the Royal Society of Medicine, American Association for Cancer Research, and other associations. One of his research interests lies in nanotechnology in cancer research and treatment. He has extensive experience in conducting investigator-initiated clinical trials and translational research. His team has authored over 100 articles and book chapters relating to cancer biology, nanotechnology, and nano-based drug delivery and genome editing, providing a balanced mix of basic and translational science to shed new light on cancer management and research. Dr. Teng has received several research awards from National Institutes of Health, Department of Defense, the industry, and other fund agencies. He also serves on a number of grant review panels, journal editorial boards, and international conference committees, demonstrating his exceptional commitment to serving the scientific community.